Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo). (December 2016) - Ward, R.; Ashton, S.; Bianco, A.; Colclough, N.; Cross, D.; Cuomo, E.; Finlay, M.R.V.; Floch, N.; Fitzek, M.; Martin, M.; Menard, L.; McKerrecher, D.; et al.